TABLE 4.

Review of previous publications regarding A2 incompatible transplantation with reported anti-A IgG titers in deceased-donor transplantation

Manuscript	No. recipients	Anti-A IgG titers pre-txp	Desensitization	Rejection	Graft survival	Patient survival	Mean serum creatinine
Nelson et al12	18 (10 group B, 8 group O recipients)	<4 (A2)	No	4 graft loss due to rejection	88% at 1 y and 80% at 2 y	2 patients died at 1 and 21 mo	N/A
Alkhunaizi et al14	15 (6 group O, 9 group B)—9 deceased donor, 6 living donor	<8 (A1)	Plasmapheresis if A titers > 1/8	1 hyperacute rejection in a patient with anti-A2 titer 1/64 and did not receive plasmapheresis, 2 acute rejection	93.3% at 1 y (combined for both deceased and living donors)	100% at 1 y (combined for both deceased and living donors)	1.3 (±0.34) mg/dL at 1 y (combined for both deceased and living donors)
Nelson et al13	41 (33 A2 to B and 4 A2B to B)	<8 (A2)	No	No data	84% at 1 y and 72% at 5 y	N/A	N/A
Bryan et al5	56 (51 A2 to B and 5 A2B to B)	<8 (A1)	No	41% acute rejection and 16% chronic rejection over 10 y	72% death-censored graft survival at 7 y	73.3% at 10 y	N/A
Williams et al4	101 (all group B recipients)	<8 (A1)	No	9.7% and 10% acute rejection at 6 mo and 1 y, respectively	85.4% at 36 mo	92.5% at 36 mo	1.4 mg/dL (0.9–2.1) at 1 y
Shaffer et al15	29 (all group B recipients)	<8 (A1)	Plasmapheresis for 5 d followed by IVIG and rituximab if anti-A2 IgG/M titers > 1/8 and ≤1/64	No data	93% at 1 y and 88% at 2 y	93% at 1 y and 88% at 2 y	1.7 mg/dL at 1 y and 1.8 mg/dL at 2 y

IVIG, intravenous immunoglobulin; N/A, not applicable.